• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Professional Introduction to 5,8-Dihydroindolo[2,3-c]carbazole (CAS No. 200339-30-6)

5,8-Dihydroindolo[2,3-c]carbazole, identified by the Chemical Abstracts Service Number (CAS No.) 200339-30-6, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the indolo[2,3-c]carbazole scaffold, a structural motif known for its broad biological activity and potential therapeutic applications. The indolo[2,3-c]carbazole class of molecules has been extensively studied due to their unique pharmacophoric properties, which make them valuable candidates for drug discovery and development.

The structural framework of 5,8-Dihydroindolo[2,3-c]carbazole consists of a fused indole and carbazole ring system, which contributes to its distinct chemical and biological characteristics. This particular compound has been investigated for its potential role in various biological pathways, including those relevant to cancer therapy, neurodegenerative diseases, and inflammation. The presence of hydrogens at the 5 and 8 positions in the molecule suggests a reduced form of the more commonly studied tetracyclic indolo[2,3-c]carbazole derivatives, which may alter its electronic properties and biological interactions.

In recent years, there has been a surge in research focused on indolo[2,3-c]carbazole derivatives due to their reported efficacy in modulating key cellular processes. Studies have demonstrated that these compounds can interact with multiple targets within cancer cells, leading to apoptosis or inhibition of tumor growth. For instance, derivatives of 5,8-Dihydroindolo[2,3-c]carbazole have been shown to exhibit inhibitory effects on kinases and other enzymes involved in cell signaling pathways critical for cancer progression. This has prompted further investigation into synthetic modifications aimed at enhancing potency and selectivity.

The pharmacological activity of 5,8-Dihydroindolo[2,3-c]carbazole is attributed to its ability to bind to specific protein targets and disrupt normal cellular functions. Preliminary studies have indicated that this compound may interfere with the activity of proteins involved in DNA replication and repair, thereby inducing cell cycle arrest or apoptosis in cancer cells. Additionally, its structural similarity to naturally occurring bioactive molecules has led researchers to explore its potential as a scaffold for designing novel therapeutic agents with improved pharmacokinetic profiles.

One of the most compelling aspects of 5,8-Dihydroindolo[2,3-c]carbazole is its versatility in chemical modification. The indolo[2,3-c]carbazole core provides multiple sites for functionalization, allowing chemists to tailor the molecule’s properties for specific biological applications. Researchers have employed various synthetic strategies to introduce substituents at key positions within the ring system, resulting in a diverse library of derivatives with enhanced biological activity. These modifications have not only improved potency but also reduced toxicity, making some derivatives more suitable for clinical development.

The synthesis of 5,8-Dihydroindolo[2,3-c]carbazole typically involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include cyclization reactions followed by functional group interconversions. Advances in synthetic methodology have enabled the production of this compound on a larger scale, facilitating further research into its biological effects. The availability of reliable synthetic protocols has also made it easier for academic and industrial researchers to explore new derivatives and evaluate their potential therapeutic value.

Recent preclinical studies have highlighted the promising applications of 5,8-Dihydroindolo[2,3-c]carbazole in treating various diseases. For example, researchers have observed significant anti-inflammatory effects when using this compound in experimental models of chronic inflammation. The ability of 5,8-Dihydroindolo[2,3-c]carbazole to modulate inflammatory pathways may make it a valuable candidate for developing treatments for conditions such as rheumatoid arthritis or inflammatory bowel disease. Furthermore, its potential role in neuroprotection has been explored in models of neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease.

The molecular interactions between 5,8-Dihydroindolo[2,3-c]carbazole and biological targets are complex and multifaceted. High-resolution structural studies have provided insights into how this compound binds to proteins such as kinases and transcription factors. These structural insights have guided efforts to optimize the molecule’s binding affinity and selectivity through rational drug design approaches. By understanding the molecular basis of its interactions， researchers can develop more effective derivatives with improved therapeutic profiles.

The future prospects for 5,8-Dihydroindolo[2,3-c]carbazole are bright， with ongoing research aimed at expanding its therapeutic applications. Novel synthetic methodologies continue to emerge， offering new opportunities for creating structurally diverse derivatives with enhanced biological activity。 Additionally， computational modeling techniques are being increasingly used to predict the binding modes of this compound with biological targets， accelerating the drug discovery process.

In conclusion,5，8-Dihydroindolo[2，3-c]carbazole(CAS No．200339-30-6) is a structurally fascinating heterocyclic compound with significant potential in pharmaceutical applications。 Its unique scaffold， combined with its versatile chemical properties， makes it an attractive scaffold for designing novel therapeutic agents。 Ongoing research continues to uncover new aspects of its biology， paving the way for innovative treatments across multiple disease areas． As our understanding of this compound grows， so too does our optimism about its future contributions to medicine．

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)